{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:treprostinil",
  "owner": "cardio",
  "kind": "drug",
  "slug": "treprostinil",
  "name": "Treprostinil",
  "aliases": [
    "Remodulin",
    "TYVASO",
    "Orenitram",
    "Treprostinil sodium",
    "Treprostinil diolamine"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Treprostinil is a prostacyclin mimetic. This page records what three US labels from one sponsor say, one for each route. The label for Remodulin, an injection formulated for subcutaneous or intravenous administration, lists pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise and, separately, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration. The label for Tyvaso, a sterile solution for oral inhalation, lists PAH to improve exercise ability and, separately, pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability. The label for Orenitram, extended-release tablets, lists PAH to delay disease progression and to improve exercise capacity. Each statement belongs to its own label and route.",
  "summary_technical": "RxNorm ingredient 343048; UNII RUM6K67ESG. MeSH has no descriptor for treprostinil (name lookups on 2026-11-18 found only supplementary concept terms), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class spelled Prostacycline Vasodilator, so the record is filed under the prostacyclin pathway page. The labels read, all by United Therapeutics Corporation, are Remodulin (NDA021272, effective 2026-07-02 in openFDA), Tyvaso (NDA022387, effective 2026-04-14) and Orenitram (NDA203496, effective 2024-11-20). Other treprostinil products and labels, including other inhaled products, were not read. Drugs@FDA lists the ingredient strings treprostinil, treprostinil sodium and treprostinil diolamine; the two salt names are kept as aliases. The statements sit in separate claims and contexts, and none gives a dose or an instruction.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "343048",
      "normalized_value": "343048",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "RUM6K67ESG",
      "normalized_value": "RUM6K67ESG",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The Remodulin label says the major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation."
  },
  "content_digest": "69b9164487a54e6855c1ec2c62f078bb13729a4a2c4a9eec80dd893797684bcc",
  "review": {
    "content_digest": "69b9164487a54e6855c1ec2c62f078bb13729a4a2c4a9eec80dd893797684bcc",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-orenitram-label-pah",
      "owner": "cardio",
      "subject_entity_id": "cardio:treprostinil",
      "category": "descriptive",
      "statement": "The US label of Orenitram (treprostinil extended-release tablets, United Therapeutics Corporation, application NDA203496; the version dated 2024-11-20 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.",
      "context": {
        "id": "cardio:ctx-fda-orenitram-label-us",
        "label": "Patients with pulmonary arterial hypertension, as described in the US label of Orenitram",
        "recipient": "unknown",
        "population": "Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the passage read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the Orenitram tablet label only. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA203496.",
          "snapshot": {
            "id": "cardio:openfda-label-orenitram-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0",
            "source_effective_date": "2024-11-20",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-orenitram",
            "source_type": "regulator",
            "title": "openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%228ed2003a-c801-411e-831e-d06079bb0d7c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-8ed2003a-c801-411e-831e-d06079bb0d7c.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20241120.",
          "snapshot": {
            "id": "cardio:openfda-label-orenitram-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0",
            "source_effective_date": "2024-11-20",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-orenitram",
            "source_type": "regulator",
            "title": "openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%228ed2003a-c801-411e-831e-d06079bb0d7c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-8ed2003a-c801-411e-831e-d06079bb0d7c.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-TRE-OR-03, Q-K30-TRE-OR-04, Q-K30-TRE-OR-05).",
          "snapshot": {
            "id": "cardio:openfda-label-orenitram-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0",
            "source_effective_date": "2024-11-20",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-orenitram",
            "source_type": "regulator",
            "title": "openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%228ed2003a-c801-411e-831e-d06079bb0d7c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-8ed2003a-c801-411e-831e-d06079bb0d7c.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "6e93f6d5dba1c1bc1a21e13a31a6629143805be44082c2cb35dbdb68b1dac52d",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-orenitram-label-pah.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-remodulin-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:treprostinil",
      "category": "descriptive",
      "statement": "The US label of Remodulin (treprostinil injection, United Therapeutics Corporation, application NDA021272; the version dated 2026-07-02 in openFDA) calls the medicine a prostacyclin mimetic, formulated for subcutaneous or intravenous administration. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.",
      "context": {
        "id": "cardio:ctx-fda-remodulin-label-us",
        "label": "Patients with pulmonary arterial hypertension, as described in the US label of Remodulin",
        "recipient": "unknown",
        "population": "Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the passage read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the Remodulin injection label only. The inhaled and oral treprostinil products have their own labels and claims. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a transition use, which sits in a separate claim.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA021272.",
          "snapshot": {
            "id": "cardio:openfda-label-remodulin-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:40Z",
            "content_hash": "8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0",
            "source_effective_date": "2026-07-02",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-remodulin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-remodulin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260702.",
          "snapshot": {
            "id": "cardio:openfda-label-remodulin-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:40Z",
            "content_hash": "8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0",
            "source_effective_date": "2026-07-02",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-remodulin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-remodulin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-TRE-RE-03, Q-K30-TRE-RE-04, Q-K30-TRE-RE-06).",
          "snapshot": {
            "id": "cardio:openfda-label-remodulin-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:40Z",
            "content_hash": "8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0",
            "source_effective_date": "2026-07-02",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-remodulin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-remodulin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "7b4db83a7361da8121bbe3db4f3f09c1cb6ebb4a72b8cfd4b6f2501d6dd0cdc9",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-remodulin-label-indications.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-remodulin-label-transition",
      "owner": "cardio",
      "subject_entity_id": "cardio:treprostinil",
      "category": "descriptive",
      "statement": "The same US label of Remodulin separately lists, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration.",
      "context": {
        "id": "cardio:ctx-fda-remodulin-label-transition",
        "label": "Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin",
        "recipient": "unknown",
        "population": "Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the passage read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients who require transition from epoprostenol, as the label states. The passage read gives no age range."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the Remodulin injection label only, and to the transition use the label names. It does not say how a transition is done, and no instruction is recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA021272.",
          "snapshot": {
            "id": "cardio:openfda-label-remodulin-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:40Z",
            "content_hash": "8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0",
            "source_effective_date": "2026-07-02",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-remodulin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-remodulin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260702.",
          "snapshot": {
            "id": "cardio:openfda-label-remodulin-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:40Z",
            "content_hash": "8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0",
            "source_effective_date": "2026-07-02",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-remodulin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-remodulin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-TRE-RE-05).",
          "snapshot": {
            "id": "cardio:openfda-label-remodulin-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:40Z",
            "content_hash": "8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0",
            "source_effective_date": "2026-07-02",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-remodulin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%226c80bb38-e8db-4138-9f0d-dbbf9c673185%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-remodulin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "4fe1d903e41c6325f3bb2c9edfce28dbc222d8211a6feed8b01b153455184cd6",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-remodulin-label-transition.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-tyvaso-label-pah",
      "owner": "cardio",
      "subject_entity_id": "cardio:treprostinil",
      "category": "descriptive",
      "statement": "The US label of Tyvaso (treprostinil, a sterile solution for oral inhalation, United Therapeutics Corporation, application NDA022387; the version dated 2026-04-14 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.",
      "context": {
        "id": "cardio:ctx-fda-tyvaso-label-pah-us",
        "label": "Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso",
        "recipient": "unknown",
        "population": "Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the passage read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the Tyvaso inhalation solution label only. Other inhaled treprostinil products have their own labels and were not read. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists pulmonary hypertension with interstitial lung disease, which sits in a separate claim.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA022387.",
          "snapshot": {
            "id": "cardio:openfda-label-tyvaso-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd",
            "source_effective_date": "2026-04-14",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tyvaso",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-cbc31ab1-a80f-4b50-a3b1-39910b0fb609.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260414.",
          "snapshot": {
            "id": "cardio:openfda-label-tyvaso-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd",
            "source_effective_date": "2026-04-14",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tyvaso",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-cbc31ab1-a80f-4b50-a3b1-39910b0fb609.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-04, Q-K30-TRE-TY-06).",
          "snapshot": {
            "id": "cardio:openfda-label-tyvaso-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd",
            "source_effective_date": "2026-04-14",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tyvaso",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-cbc31ab1-a80f-4b50-a3b1-39910b0fb609.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "899f1af72a79f3da4875e97c7f1d3f96421530601e5bf2a18a0ad8fb5d051bd2",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-tyvaso-label-pah.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-tyvaso-label-ph-ild",
      "owner": "cardio",
      "subject_entity_id": "cardio:treprostinil",
      "category": "descriptive",
      "statement": "The same US label of Tyvaso separately lists treating pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.",
      "context": {
        "id": "cardio:ctx-fda-tyvaso-label-ph-ild-us",
        "label": "Patients with pulmonary hypertension associated with interstitial lung disease, as described in the US label of Tyvaso",
        "recipient": "unknown",
        "population": "Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the passage read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim is tied to the Tyvaso inhalation solution label only, and concerns a different group of pulmonary hypertension from pulmonary arterial hypertension. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA022387.",
          "snapshot": {
            "id": "cardio:openfda-label-tyvaso-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd",
            "source_effective_date": "2026-04-14",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tyvaso",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-cbc31ab1-a80f-4b50-a3b1-39910b0fb609.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260414.",
          "snapshot": {
            "id": "cardio:openfda-label-tyvaso-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd",
            "source_effective_date": "2026-04-14",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tyvaso",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-cbc31ab1-a80f-4b50-a3b1-39910b0fb609.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-05, Q-K30-TRE-TY-06).",
          "snapshot": {
            "id": "cardio:openfda-label-tyvaso-2026-11-19",
            "retrieved_at": "2026-11-19T02:47:45Z",
            "content_hash": "3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd",
            "source_effective_date": "2026-04-14",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tyvaso",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22cbc31ab1-a80f-4b50-a3b1-39910b0fb609%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k30-openfda-label-cbc31ab1-a80f-4b50-a3b1-39910b0fb609.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "5cbe68b8782a307ab47d3a8f470015f14fe68d4c539c3cf9617c94828b5af2fe",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-tyvaso-label-ph-ild.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Treprostinil is a prostacyclin vasodilator in RxClass spelling (FDA established pharmacologic class)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:prostacyclin-pathway-drugs",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-343048-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[2].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label for the Remodulin injection lists pulmonary arterial hypertension (WHO Group 1), to diminish symptoms associated with exercise, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-remodulin-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label for the Remodulin injection separately lists patients who require transition from epoprostenol as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-remodulin-label-transition",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label for the Tyvaso inhalation solution lists pulmonary arterial hypertension (WHO Group 1), to improve exercise ability, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-tyvaso-label-pah",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label for the Tyvaso inhalation solution separately lists pulmonary hypertension associated with interstitial lung disease (WHO Group 3) as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-tyvaso-label-ph-ild",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label for the Orenitram tablets lists pulmonary arterial hypertension (WHO Group 1), to delay disease progression and to improve exercise capacity, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-orenitram-label-pah",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/treprostinil/",
  "context_path": "api/v1/context/cardio--treprostinil.md"
}
